Cystic Fibrosis Clinical Trial
Official title:
A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele
Verified date | July 2021 |
Source | Eloxx Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least one G542X allele or phenotypically similar nonsense allele. Up to 16 patients will be enrolled in the trial; up 4 patients will be homozygotes to G542X, and the remaining patients will be compound heterozygotes with G542X or phenotypically similar nonsense mutation and any Class 1 or Class 2 mutation. Each patient will receive 5 escalating doses as follows: - 0.3 mg/kg per day SC - 0.75 mg/kg per day SC - 1.5 mg/kg per day SC - An individualized dose, as high as 3.0 mg/kg per day SC, based upon the patients observed safety and tolerability, PK at previous doses and the results of laboratory tests - ELX-02 1.5 mg/kg per day SC plus 150 mg ivacaftor every 12 bid
Status | Completed |
Enrollment | 17 |
Est. completion date | April 6, 2022 |
Est. primary completion date | April 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Patients must meet the following criteria to participate in this study: 1. Males and females age 18 years and above in Germany and Israel; in countries where permitted, males and females age 16 years and above 2. A confirmed diagnosis of nmCF with a documented G542X or phenotypically similar nonsense mutation, homozygote, or compound heterozygote with one of the specified mutations. For heterozygotes, one mutation has to be G542X or phenotypically similar nonsense mutation, and the second mutation could be and Class 1 or Class 2 mutation. Patients with one G542X or phenotypically similar nonsense allele and a second allele that is not in the above list may be potentially allowed but only after discussion on a case by case basis with and written approval from the Sponsor. 3. Documented SCC = 60 mEq/L 4. FEV1 = 40% predicted normal for age, gender and height at Screening (Knudson Equation) 5. Body Mass Index (BMI) of 19.0 to 30.0 kg/m2 (inclusive). Patients with any of the following characteristics/conditions will not be included in the study: 1. Participation in clinical study including administration of any investigational drug or device in the last 30 days or 5 half-lives (whichever is longer) prior to investigational product dosing in the current study 2. History of any organ transplantation 3. Major surgery within 180 days (6 months) of Screening 4. Patients without documented prior aminoglycoside exposure who have a mitochondrial mutation that has been shown to increase sensitivity to aminoglycosides 5. Known allergy to any aminoglycoside 6. Patients with any abnormality at ENT screening, that indicates the presence of a vestibular toxicity associated with prior exposure to aminoglycosides. 7. Dizziness Handicap Inventory (DHI)-H score at screening >16 8. Patients receiving CFTR modulators within 2 months of study treatment |
Country | Name | City | State |
---|---|---|---|
Australia | The Royal Adelaide Hospital | Adelaide | South Australia |
Australia | The Royal Prince Alfred Hospital | Camperdown | New South Whales |
Australia | The Alfred Hospital | Melbourne | Victoria |
Germany | Universitätsmedizin Essen Ruhrlandklinik | Essen | North Rhine-Westphalia |
Germany | Universitätsklinikum Frankfurt | Frankfurt | |
Israel | Carmel Medical Center | Haifa | |
Israel | Hadassah Medical Center | Jerusalem | |
Israel | Schneider Children's Medical Center | Petach Tikvah | |
Israel | Safra Children's Hospital - Chaim Sheba Medical Center | Ramat Gan |
Lead Sponsor | Collaborator |
---|---|
Eloxx Pharmaceuticals, Inc. |
Australia, Germany, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AEs associated with different dose levels of ELX-02 | From the time of first dosing through the follow-up visit, an average of approximately 9 weeks | ||
Primary | Area under the plasma concentration curve from time zero to 24 hours (AUC0-24) | Full PK profile 8 blood samples up to 24 hours | Day 1 of treatment periods 1, 2, 3, and 4 | |
Primary | Maximum observed plasma concentration (Cmax) on Day 1 | Full PK profile 8 blood samples over 24 hours | Day 1 of treatment periods 1, 2, 3, and 4 | |
Primary | Peak observed plasma concentration (Cpeak) over time | Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7, and 14 of treatment period 4, sparse sampling, blood sampling at 30 min and 1 hour post-dose | ||
Primary | Trough observed plasma concentrations (Cpredose) over time | Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7 and 14 of treatment period 4, sparse blood sampling at pre-dose | ||
Secondary | Changes from baseline in sweat chloride concentration | From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4 | ||
Secondary | Changes from baseline in percent predicted forced expiratory volume (ppFEV1) | From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4 | ||
Secondary | Changes from baseline in percent predicted forced vital capacity (ppFVC) | From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4 | ||
Secondary | Changes from baseline in percent predicted forced expiratory flow at 25-75% (ppFEF25-75) | From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |